Mantle Cell Lymphoma (MCL) Completed Phase 2 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00490529Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCLTreatment
NCT00875667A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Treatment
NCT00992134Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaTreatment
NCT00038623Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell LymphomaTreatment
NCT00186628Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHDTreatment
NCT00980395Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaTreatment
NCT00201877Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaTreatment
NCT01737177Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLTreatment
NCT01562977Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLTreatment
NCT00891839Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaTreatment
NCT01662050Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCLTreatment
NCT00119730Chemotherapy Followed by Zevalin for Relapsed Mantle Cell LymphomaTreatment
NCT00225212Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's LymphomaTreatment
NCT00285389Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 YearsTreatment
NCT00472420A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.Treatment
NCT00581776Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaTreatment
NCT00609869Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabTreatment
NCT00958256Study of Bortezomib in Combination With Cyclophosphamide and RituximabTreatment